Slide 1Presenter Disclosure Information Jochen Senges The following relationships exist related to this presentation: Speaker CompensationTrommsdorff ArzneimittelModest Level…
Slide 1DAIDS Safety Workshop: Part III Expedited Reporting via DAERS Albert Yoyin, M.D. and Archita Chatterjee, M.S. DAIDS RSC Safety Office Johannesburg, South Africa 29…
Slide 1Phase-III Studie: HECTOR Topotecan plus Carboplatin (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) -Intergroup Study of NOGGO und Studiengruppe Ovar…
Slide 1Presenter Disclosure Information Jochen Senges The following relationships exist related to this presentation: Speaker CompensationTrommsdorff ArzneimittelModest Level…
Slide 1Switch ABC/3TC to TDF/FTC SWIFT Study Slide 2 SWIFT Study: Switch ABC/3TC to TDF/FTC Design Campo R, CID 2013, Jan 29 (epub ahead of print) LPV/rATV/rFPV +…
Slide 1 Adapted from the PMB through CTEP 2008 (revised 09/2014) NCORP-KC Guidelines for Investigational Drug Management Slide 2 Introduction Physician is ultimately responsible…
Slide 1 The ESETT Study Principal Investigator Name Slide 2 What is Status Epilepticus? Status Epilepticus is seizure activity that does not stop It can cause unconsciousness…
Slide 1 Andrew Henriksen PBM-CMOP Slide 2 Compares of the value of one drug or drug therapy to another Provides guidance to allocate resources Identifies efficiencies…
Slide 1 Slide 2 1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri Slide 3 2 FDA Thailand Introduction Drugs registration The effect of FDA on Marketing…
Slide 1 ClinicalTrials.gov Results Reporting from the Ground Up [Presenter Name and contact Info] 1 Slide 2 Purpose of Template Presentation This presentation was compiled…